Who are cTACE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eloxatin, PLD, Folfox-7, PUVA (8MOP + UVA) + IFN, Folfiri, Chemotherapy+Pembrolizumab..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ctace.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

cTACE — Competitive Intelligence Brief

cTACE (cTACE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: chemotherapy. Area: Oncology.

phase 3 chemotherapy Oncology Small molecule Live · refreshed every 30 min

Target snapshot

cTACE (cTACE) — Chengdu New Radiomedicine Technology Co. LTD.. cTACE involves the direct injection of chemotherapy drugs into liver tumors via the hepatic artery.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
cTACE TARGET	cTACE	Chengdu New Radiomedicine Technology Co. LTD.	phase 3	chemotherapy
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
PLD	PLD	AGO Research GmbH	marketed	Pegylated liposomal chemotherapy	DNA (topoisomerase II inhibitor via doxorubicin)
Folfox-7	folfox-7	Pfizer	marketed	chemotherapy	DNA replication machinery
PUVA (8MOP + UVA) + IFN	PUVA (8MOP + UVA) + IFN	Madrilenian Group of Cutaneous Lymphomas	marketed	Photochemotherapy + cytokine combination
Folfiri	folfiri	Pfizer	marketed	chemotherapy	DNA replication and repair
Chemotherapy+Pembrolizumab.	Chemotherapy+Pembrolizumab.	Tang-Du Hospital	marketed	Chemotherapy + PD-1 inhibitor combination	PD-1 (programmed death receptor 1); chemotherapy targets DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (chemotherapy class)

Pfizer · 3 drugs in this class
Chengdu New Radiomedicine Technology Co. LTD. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 drug in this class
Chinese Society of Lung Cancer · 1 drug in this class
Hutchmed · 1 drug in this class
Prof. Massimo Aglietta · 1 drug in this class
Sanofi · 1 drug in this class
Sun Yat-sen University · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Swiss Cancer Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cTACE — Competitive Intelligence Brief. https://druglandscape.com/ci/ctace. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab